Antimicrobial resistance (AMR) in Neisseria gonorrhoeae seriously compromises the management and control of gonorrhea. Enhanced international collaborative actions are crucial for the control of gonorrhea, including improved prevention, early diagnosis (development of accurate, rapid, point-of-care tests), partner management, and enhanced surveillance (including population-based surveillance and surveillance of treatment failures and antimicrobial use). Rapid, accurate, point-of-care diagnostic tests (which would ideally predict AMR and/or antimicrobial susceptibility), new therapeutic drugs, and a gonococcal vaccine – which will ultimately be the only sustainable way to achieve gonorrhea control – are needed.